Anti-SIRPα Antibodies: A Promising Avenue for Immunotherapy

Conventional cancer therapies such as chemotherapy and radiation have a significant downfall: while targeting cancerous tumors, they also damage healthy cells which can lead to undesirable patient side-effects. Despite high expectations at the onset, treatments using monoclonal antibodies have historically faced limitations. While attempting to discover why monoclonal antibodies were not performing as expected, researchers…

Thank You for a Great 2017!

It’s hard to believe 2017 is coming to a close in just a few short days. What a year it has been! There have been many groundbreaking immunotherapy innovations this year. From the first-ever FDA-approved CAR-T cell therapy to the federal PACT initiative investing $215 million in immunotherapy research to countless other advancements, it’s incredible…

Novartis Earns Unanimous Recommendation for FDA Approval of CAR-T Cell Therapy

We may not have to wait much longer for the first FDA-approved CAR-T cell therapy. The Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) recently recommended Novartis’ CTL019 CAR-T cell therapy for FDA approval by unanimous decision, a major step forward for the groundbreaking biologic. CTL019, indicated for pediatric and young adult r/r B…